Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06700841 Immediate release · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-06700841: IR followed by MR | EXPERIMENTAL | Participants receive PF-06700841 Immediate release tablets (IR) followed by PF-06700841 Modified release tablets (MR) |
| PF-06700841: MR followed by IR | EXPERIMENTAL | Participants receive PF-06700841 Modified release tablets (MR) followed by PF-06700841 Immediate release tablets (IR) |
| Name | Type | Description |
|---|---|---|
| PF-06700841 Immediate release tablets | DRUG | Small molecule tablets in immediate release form |
| PF-06700841 Modified release tablets | DRUG | Small molecule tablets in modified release form |
Key Inclusion Criteria: * Healthy male, and female participants between the ages of 18 and 55 years at the time of screening, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse...
PF-06700841 Immediate release is an investigational small molecule being studied in healthy participants. It is currently in Phase 1 clinical development, with a completed trial evaluating blood concentrations after oral dosing. The drug is not approved and remains in clinical development.
PF-06700841 Immediate release is being developed by Pfizer, Inc. (NYSE: PFE). The company is conducting clinical trials to evaluate the drug's pharmacokinetics in healthy participants.
PF-06700841 Immediate release is in Phase 1 clinical development. One Phase 1 trial has been completed, and the drug remains investigational. It is not approved for any use.
PF-06700841 Immediate release has one completed clinical trial, NCT03765554, titled 'Clinical Study to Evaluate Blood Concentrations of PF-06700841 After Oral Dose as Different Formulations.' This Phase 1 study enrolled 8 healthy participants in Belgium.
PF-06700841 Immediate release is a formulation of the investigational drug PF-06700841. The immediate release version is being studied to evaluate blood concentrations after oral dosing, as part of the drug's clinical development program.